OmniPathology on Tuesday announced the launch of an oral lab-developed test for human papillomavirus (HPV) performed on the Roche Cobas 6800 and 8800 high-throughput molecular diagnostic platforms.
The PCR-based test detects 14 high-risk strains of HPV, a virus with potential to progress to cancer. It is performed on a throat swab submitted for testing to OmniPathology's CLIA-certified laboratory in Pasadena, CA, and helps screen for oropharyngeal cancer and early premalignant lesions.
"We continue to build our testing menu to target sexually transmitted infections and other viral diseases," Dr. Mohammad Kama, founder and CEO of OmniPathology, a physician-owned and operated pathology lab, said in a statement.